drugset
drugset / Trial / NCT05109078

ADME Study of [14C]- Rongliflozin in Healthy Male Subjects

NCT05109078 ↗

Phase 1 Completed 6 enrolled Sunshine Lake Pharma Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

Study to Evaluate the Mass Balance and Biotransformation of Single Dose \[14C\]- Rongliflozin in healthy male subjects.

Timeline

Start
2021-12-09
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Rongliflozin Small molecule 50 mg Oral

Indications

No indication recorded.